Epigenetics Market Report 2026

Epigenetics Market Overview

• Epigenetics market size has reached to $12.74 billion in 2025 • Expected to grow to $35.01 billion in 2030 at a compound annual growth rate (CAGR) of 22.3% • Growth Driver: Precision Medicine Drives Growth Of Epigenetics Market • Market Trend: AI-Driven Analytics Transforming Epigenetics Research And Data Analysis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Epigenetics Market?

Epigenetics is a change in gene activity transmitted to younger cells without modifying the DNA sequence. Epigenetic processes are natural and necessary for many organisms to work, but unusual occurrences can cause disorders, such as various types of cancer, reproductive illnesses, and cardiovascular illnesses. Epigenetics is used detect a type of cancers earlier. The main products used in epigenetics market are reagents, enzymes, instruments and kits. Reagents are compounds or substances that are used for chemical analysis or epigenetic testing. DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification and chromatin structures are the technologies used in epigenetics. The application included oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases and other applications. These epigenetics are used by academic and research institutes, pharmaceutical, and biotechnology companies, contract research organizations and other end users.

What Is The Epigenetics Market Growth Forecast?

The epigenetics market size is expected to see exponential growth in the next few years. It will grow to $35.01 billion in 2030 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to increasing investments in precision medicine, rising adoption of epigenetic therapeutics, expansion of personalized oncology treatments, growing use of ai-driven genomic analysis, increasing collaboration between pharma and research institutes. Major trends in the forecast period include increasing use of epigenetic biomarkers in oncology, rising adoption of high-throughput epigenetic analysis tools, growing demand for dna methylation assays, expansion of epigenetics-based drug discovery, enhanced integration of bioinformatics platforms.

Global Epigenetics Market Segmentation

1) By Product: Reagents, Enzymes, Instruments, Kits 2) By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures 3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications 4) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Other End Users Subsegments: 1) By Reagents: DNA Methylation Reagents, Histone Modification Reagents, RNA Modifications Reagents, Enzymes 2) By Enzymes: DNA Methyltransferases, Histone Acetyltransferases, Histone Deacetylases 3) By Instruments: Sequencers, PCR Machines, Microarray Platforms, Mass Spectrometers 4) By Kits: DNA Methylation Kits, Chromatin Immunoprecipitation (ChIP) Kits, RNA-Seq Kits, Bisulfite Conversion Kits

What Is The Driver Of The Epigenetics Market?

An increasing focus on precision medicine is expected to propel the growth of the epigenetics market going forward. Precision medicine is a medical approach that considers an individual's genetic, environmental, and lifestyle information to customize treatment to their specific needs. Precision medicine in epigenetics uses individual epigenetic profiles and genetic data to create personalized healthcare strategies for more effective disease management and treatment of each patient. For instance, in March 2024, Novotech, an Australia-based biotechnology company, in 2023, 43% of the 217 FDA-approved oncology therapies were precision oncology treatments, with 78 incorporating DNA or NGS-detectable biomarkers. Therefore, an increasing focus on precision medicine is driving the growth of the epigenetics industry.

Key Players In The Global Epigenetics Market

Major companies operating in the epigenetics market are Illumina Inc., Thermo Fisher Scientific, Merck Millipore, Active Motif, Abcam PLC, Qiagen NV, Diagenode SA, CellCentric Ltd., Chroma Medicine Inc., Constellation Pharmaceuticals Inc., Domainex Ltd., Eisai Co. Ltd., Epigen Biosciences Inc., EpigenDx Inc., Epigenomics AG, Epizyme Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., MDxHealth SA, Novartis AG, OncoDNA SA, Oryzon Genomics S.A., Pfizer Inc., Syndax Pharmaceuticals Inc., Valirx plc

Global Epigenetics Market Trends and Insights

Major companies operating in the epigenetics market are increasing their focus on introducing artificial intelligence (AI)-driven analytics to gain a competitive edge in the market. AI-driven analytics is the process of using artificial intelligence (AI) technologies to automatically analyze and interpret large volumes of data. For instance, in July 2023, FOXO Technologies, a US-based company, launched Bioinformatics Services to revolutionize epigenetic data analysis. FOXO's Bioinformatics Services provide a versatile platform of advanced data solutions customized to address the specific requirements of clients engaged in academia, healthcare, and pharmaceutical research. Innovative bioinformatic tools Using an innovative suite of bioinformatic tools, FOXO aims to enable its clients to increase the speed and accuracy with which they process, analyze, and interpret data sets, accelerate discoveries, and advance their understanding of complex diseases.

What Are Latest Mergers And Acquisitions In The Epigenetics Market?

In July 2023, New Day Diagnostics, a US-based provider of molecular and epigenetic diagnostic technologies, acquired substantially all of the assets of Epigenomics AG for an undisclosed amount. With this acquisition, New Day Diagnostics aims to strengthen its precision-epigenetic diagnostics portfolio, expand its cancer biomarker offerings, and enhance its technological capabilities in DNA methylation-based testing. Epigenomics AG is a Germany-based provider of DNA methylation-based in vitro diagnostic tests for cancer.

Regional Outlook

North America was the largest region in the epigenetics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the epigenetics market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Epigenetics Market?

The epigenetics market includes revenues earned by entities methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.